

# Bio-Techne Divested Assets of Its Subsidiary, Atlanta Biologicals, to GeminiBio



Divested Assets to



69th

Diagnostics &  
Tools  
Transaction

2nd

Bio Specimen  
Deal

*Bio-Techne Divested Fetal Bovine Serum Product Rights and Inventory from Its Subsidiary, Atlanta Biologicals, to GeminiBio*

**The Life Sciences market, particularly in the** Diagnostics and Tools and Reagents and Consumables sectors, is undergoing transformative growth fueled by advances in precision medicine and the rising demand for scalable, cost-effective research solutions. As companies seek to expand and/or reposition their capabilities, strategic acquisitions and divestitures are reshaping the competitive landscape.

**Bio-Techne continues to empower researchers and** clinicians through its robust portfolio of innovative tools and reagents, including proteins, antibodies, and cell and gene therapy solutions. As part of honing its strategic focus, Bio-Techne has divested select fetal bovine serum (FBS) product rights and inventory, previously managed by its subsidiary Atlanta Biologicals, to GeminiBio. GeminiBio, a trusted provider of high-quality

reagents, cell culture solutions, and services for cell and gene therapy development, biomanufacturing, and life sciences research, is well-positioned to take over these assets and ensure continuity for customers.

**Crosstree played a central role in facilitating** this transaction, leveraging its deep expertise in the cell culture and biological consumables field. By identifying and evaluating a select group of strategic partners, Crosstree ensured alignment with Bio-Techne's goals of maintaining product quality and customer experience. Through a comprehensive evaluation of transaction alternatives, Crosstree successfully identified GeminiBio as the ideal partner, enabling both companies to achieve corporate objectives.

“Crosstree’s proven track record of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today.”



**JEFF ELLIS**

Managing Director & Co-Founder  
[jeff.ellis@crosstreecapital.com](mailto:jeff.ellis@crosstreecapital.com)  
(813) 774-4753

Crosstree's experts are specialists in the nuances of the health sciences, prioritizing corporate core values and providing:

<p>Deep analytics of capabilities and gaps</p>	<p>Systemized tactical strategies and a road map to success</p>	<p>Engaged experts in market analysis, financials, and premium valuations</p>	<p>Targeted and qualified prospects</p>	<p>Up-to-date industry trend analysis and forecasting</p>
--	---	---	---	---

Meeting the needs of both the buyer and the seller by the numbers and beyond is Crosstree's specialty.



### About Bio-Techne

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately \$1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide

### About GeminiBio

Founded in 1985, GeminiBio serves the global biotechnology industry, from basic research to commercial production, with a focus on helping customers accelerate the development of life-enhancing biotherapeutics by streamlining and improving their cell culture and process liquid manufacturing workflows. The company's products are organized into two core verticals – Cell Culture Solutions and Process Liquid Solutions. Located in West Sacramento, California, GeminiBio has 57,000 square feet of cGMP manufacturing space, segregated between animal origin-free and animal component manufacturing.



### Other Recent Health Sciences Transactions:

**Project Gateway**  
(Pending)

Specialty Pharmacy Supply-Chain & Infusion Practice Management Software

**oanju**

Acquired by

**VALSOFT**

**CALYX**

Divested its 'Enterprise Technology' Division to

**eNNOV**  
Software for Life

**physIQ**

Acquired by

**prolaio**

**PINNACLE**  
CLINICAL RESEARCH  
A portfolio company of

**LVC**  
LONGUEVUE CAPITAL  
Acquired

**KERWIN MEDICAL**  
CENTER

**BBi Solutions**  
A Portfolio Company of

**NOVO**  
holdings  
Acquired

**IBEX**